Scientific Motivation

Recent breakthroughs in cancer research have revolutionised our understanding of the molecular pathology of cancer. Nevertheless, the success of currently available targeted cancer therapies is limited and the development of novel treatment options is slow.

To accelerate the translation of research findings to novel therapeutics and diagnostics, the German Cancer Research Center and Bayer Schering Pharma have joined forces and set up a strategic alliance.

The Symposium is held within the framework of this partnership. It will bring together basic and clinical researchers to present their recent research findings relevant to the identification of novel targets or the development of novel therapeutic strategies, and to discuss established and emerging frontiers of targeted cancer therapies. Scientific and clinical aspects will be reviewed in the context of anti-angiogenesis, signal transduction and chromatin modulation.

We cordially invite you to the stimulating environment and “scientific hot spot” of Heidelberg to discuss with us this exciting field bridging basic discovery research in the field of oncology with translational exploitation.

Scientific Organizing Committee

General Information

Venue
German Cancer Research Center (DKFZ)
Communication Center
Im Neuenheimer Feld 280
69120 Heidelberg, Germany
http://www.dkfz.de

Scientific Coordination and Local Organisation
Ruth Wellenreuther
German Cancer Research Center (DKFZ)
Heidelberg
Phone +49. 6221. 42 21 69
Mobile +49. 173. 904 86 14
e-mail r.wellenreuther@dkfz-heidelberg.de

Ingrid Fryson
German Cancer Research Center (DKFZ)
Heidelberg
Phone +49. 6221. 42 37 16
e-mail i.fryson@dkfz-heidelberg.de

Symposium
: Targeted Cancer Therapy.

May 10 – 11, 2010
German Cancer Research Center (DKFZ)
Heidelberg
## Programme

### Monday, May 10, 2010

**Opening**
- **Chair**: Christof von Kalle
- **_17:00_**
  - Otmar Wiestler
    - Chairman and Scientific Director
    - German Cancer Research Center (DKFZ), Heidelberg
    - Welcome address

**17:10**
- **Keynote lecture I**
  - Carl-Henrik Heldin
    - Director of the Ludwig Institute for Cancer Research, Uppsala
    - Title: Signaling via receptors for PDGF and TGF-beta: possible targets in tumor therapy.

**18:10**
- **Keynote lecture II**
  - José Baselga
    - Chairman & Professor of Medicine, Vall d’Hebron Institute of Oncology (V.H.I.O.), Vall d’Hebron University Hospital, Barcelona
    - Title to be announced.

**19:00**
- **Reception and get-together**

### Tuesday, May 11, 2010

**Session I** : Anti-Angiogenesis.
- **Chairs**: Hellmut Augustin, Holger Hess-Stumpf
- **_9:00_**
  - Eckhard Lammeret
    - Institut für Stoffwechselphysiologie, Heinrich-Heine-Universität Düsseldorf
    - Formation of the first blood vessel.
- **_9:30_**
  - Peter Carmeliet
    - Vesalius Research Center, K. U. Leuven, Belgium
    - Title to be announced.
- **_10:00_**
  - Adrian Harris
    - Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford
    - New mechanisms of NOTCH signalling and resistance to anti-VEGF therapy.
- **_10:30_**
  - Robert Kerbel
    - Molecular and Cellular Biology Research, Sunnybrook Health Sciences Centre, Toronto
    - Targeted (and ‘non-targeted’) vascular therapy of the tumor microenvironment.

**11:00**
- **Coffee break**

**Session II** : Chromatin Modulation.
- **Chairs**: Bernard Haendeler, Frank Lyko
- **_11:30_**
  - Paul A. Marks
    - Memorial Sloan-Kettering Cancer Center, New York
    - Histone deacetylase inhibitors: bench to bedside.
- **_12:00_**
  - Rob Klose
    - Department of Biochemistry, University of Oxford
    - Title to be announced.
- **_12:30_**
  - Lunch

**Session III** : Signal Transduction.
- **Chairs**: Peter Angel, Gerhard Siemeister
- **_14:00_**
  - Kristian Helin
    - Biotech Research and Innovation Centre (BRIC) and Centre for Epigenetics, University of Copenhagen
    - Title to be announced.
- **_14:30_**
  - Maarten van Lohuizen
    - Molecular Genetics Division, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam
    - Title to be announced.
- **_15:00_**
  - Neal Rosen
    - Molecular Pharmacology & Chemistry, Memorial Sloan-Kettering Cancer Center, New York
    - Title to be announced.
- **_15:30_**
  - Chi Dang
    - Department of Medicine-Hematology Division, Johns Hopkins University School of Medicine, Baltimore
    - Targeting Myc and HIF induced alterations of cancer metabolism.
- **_16:00_**
  - Coffee break
- **_16:30_**
  - Geert Kops
    - Department of Physiological Chemistry and Cancer Genomics Centre, UMC Utrecht, Utrecht
    - Maintenance of genomic stability by mitotic kinases.
- **_17:00_**
  - Michael Karin
    - Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California San Diego, La Jolla
    - Title to be announced.
- **_17:30_**
  - End of symposium